- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02260180
Study of A-101 for the Treatment of Seborrheic Keratosis
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Dose-Response Profile of A-101 Topical Solution in Subjects With Seborrheic Keratosis of the Face
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97223
- Oregon Medical Research Center
-
-
Pennsylvania
-
Fort Washington, Pennsylvania, United States, 19034
- Philadelphia Institute of Dermatology
-
-
Texas
-
Austin, Texas, United States, 78759
- DermReseach, Inc.
-
-
Virginia
-
Lynchburg, Virginia, United States, 24501
- The Education & Research Foundation, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is at least 18 years of age
- Subject has a Fitzpatrick skin type of 1-4
- Subject has a clinical diagnosis of stable clinically typical seborrheic keratosis
Subject has 1 appropriate seborrheic keratosis target lesion, as defined below (Section 5.4), on the face:
- Have a clinically typical appearance
- Be treatment naïve
- Have a Physician's Lesion Assessment (PLA) of ≥2 (Section 6.1.2)
- Have a longest axis that is ≥7mm and ≤15mm (Section 5.4)
- Have a longest dimension perpendicular to the longest axis that is ≥7mm and ≤15mm (Section 5.4)
- Have a thickness that is ≤2mm
- Be a discrete lesion
- Be, when centered in the area outlined by the provided 3cm diameter circular template, the only seborrheic keratosis lesion present
- Not be on the eyelids
- Not be within 5mm of the orbital rim
- Not be covered with hair which, in the investigator's opinion, would interfere with the study medication application or the study evaluations (NB: the study medication may bleach hair)
- Not be in an intertriginous fold
- Not be pedunculated.
- If the subject is a woman of childbearing potential, she has a negative urine pregnancy test and agrees to use an approved effective method of birth control (Section 8) for the duration of the study
- Subject is non-pregnant and non-lactating
- Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair evaluation of the target lesion or which exposes the subject to an unacceptable risk by study participation
- Subject is willing and able to follow all study instructions and to attend all study visits
- Subject is able to comprehend and willing to sign an Informed Consent Form (ICF).
Exclusion Criteria:
- Subject has clinically atypical and/or rapidly growing seborrheic keratosis lesions
- Subject has presence of multiple eruptive seborrheic keratosis lesions (Sign of Leser-Trelat)
- Subject has a current systemic malignancy
- Subject has a history of keloid formation or hypertrophic scarring
Subject has used any of the following systemic therapies within the specified period prior to Visit 1:
- Retinoids; 180 days
- Glucocortico-steroids; 28 days
- Anti-metabolites (e.g., methotrexate); 28 days
Subject has used any of the following topical therapies within the specified period prior to Visit 1 on, or in a proximity to the target lesion, which in the investigator's opinion, interferes with the application of the study medication or the study assessments:
- LASER, light (e.g., intense pulsed light (IPL), photo-dynamic therapy(PDT)) or other energy based therapy; 180 days
- Retinoids; 28 days
- Liquid nitrogen, electrodesiccation, curettage, imiquimod, 5-fluorouracil, or ingenol mebutate; 60 days
- Glucocortico-steroids or antibiotics; 14 days
Subject currently has or has had any of the following within the specified period prior to Visit 1 on, or in a proximity to the target lesion, which in the investigator's opinion, interferes with the application of the study medication or the study assessments :
- A cutaneous malignancy; 180 days
- Experienced a sunburn; 28 days
- A pre-malignancy (e.g., actinic keratosis); currently
- Body art (e.g., tattoos, piercing, etc.); currently
- Excessive tan; currently
- Subject has a history of sensitivity to any of the ingredients in the study medications
- Subject has any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage, etc.), or condition (e.g., sunburn, excessive hair, open wounds) which, in the investigator's opinion, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations
- Subject has participated in an investigational drug trial in which administration of an investigational study medication occurred within 30 days prior to Visit 1.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A-101 40%
A-101 40% Topical Solution
|
Topical Solution
|
Active Comparator: A-101 32.5%
A-101 32.5% Topical Solution
|
Topical Solution
|
Placebo Comparator: A-101 Vehicle Topical Solution
A-101 0% Topical Solution (vehicle)
|
Topical Solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of PLA Responders With Target Lesion Clear (PLA = 0) in Each Arm at Visit 8.
Time Frame: Day 106
|
The primary effectiveness analysis was a comparison between each A-101 group and the vehicle group based on the percentage with target lesions judged to be clear on the PLA (PLA = 0) at Visit 8.
The three arms of the study are A-101 40% Topical Solution, A-101 32.5% Topical Solution, and A-101 0% Topical Solution (vehicle).
The Physician's Lesion Analysis ( PLA) is a 4 point scale from 0 to 3, with 0 being lesion clear and 3 being the most severe lesion.
A larger proportion of subjects with a PLA =0 is better.
|
Day 106
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline PLA Score at Visit 8
Time Frame: Day 106
|
A secondary efficacy analysis was the mean change from baseline PLA Score at visit 8.
The three arms of the study are A-101 40% Topical Solution, A-101 32.5% Topical Solution, and A-101 0% Topical Solution (vehicle).
The Physician's Lesion Analysis ( PLA) is a 4 point scale from 0 to 3, with 0 being lesion clear and 3 being the most severe lesion.
A larger proportion of subjects with a PLA =0 is better.
A lower (more negative) mean change is a better outcome.
|
Day 106
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Brian Beger, BS, Aclaris Therapeutics, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A-101-SEBK-203
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seborrheic Keratosis
-
Aclaris Therapeutics, Inc.CompletedSeborrheic Keratosis (SK)United States
-
PeplinCompletedSeborrheic KeratosisAustralia
-
DermBiont, Inc.Active, not recruitingA Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic KeratosisSeborrheic KeratosisUnited States
-
DermBiont, Inc.Zepeda DermatologiaActive, not recruitingSeborrheic KeratosisEl Salvador
-
Aclaris Therapeutics, Inc.CompletedSeborrheic KeratosisUnited States
-
Milton S. Hershey Medical CenterCompletedSeborrheic KeratosisUnited States
-
University of California, DavisCompleted
-
Aclaris Therapeutics, Inc.CompletedSeborrheic KeratosisUnited States
-
Pulse Biosciences, Inc.CompletedSeborrheic Keratosis | Lesion SkinUnited States
-
Indonesia UniversityCompletedSeborrheic Keratosis | AcrochordonIndonesia
Clinical Trials on A-101
-
Aclaris Therapeutics, Inc.CompletedSeborrheic Keratosis (SK)United States
-
Aclaris Therapeutics, Inc.CompletedSeborrheic KeratosisUnited States
-
Aclaris Therapeutics, Inc.CompletedCommon WartUnited States
-
Aclaris Therapeutics, Inc.Completed
-
Aclaris Therapeutics, Inc.Completed
-
Aclaris Therapeutics, Inc.Completed
-
Applied Molecular TransportCompletedPouchitisUnited States, Canada, France, Spain, United Kingdom, Germany, Belgium, Hungary, Netherlands, Switzerland
-
Aclaris Therapeutics, Inc.CompletedDermatosis Papulosa NigraUnited States
-
Aclaris Therapeutics, Inc.CompletedSeborrheic KeratosisUnited States
-
Aclaris Therapeutics, Inc.CompletedSeborrheic KeratosisUnited States